The evidence so far is that ADT is not necessary when used with extreme hypofractionated radiation like SBRT and HDR brachytherapy. There have been no randomized clinical trials yet.
Alan Katz (see link) included in his study 51 patients who received up to 6 months of ADT with their SBRT and found "Our data also show no significant benefit for use of of ADT."
/www.ncbi.nlm.nih.gov/pmc/articles/PMC4150980/Jeff Demanes found there was no benefit to adding ADT for any risk group when using HDR brachy combined with external beam radiation:
Excellent Results From High Dose Rate Brachytherapy and External Beam for Prostate Cancer are Not Improved by Androgen DeprivationLack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regimeThe lack of benefit for intermediate risk patients (but not for high risk patients) was observed in this German study:
/www.ncbi.nlm.nih.gov/pubmed/25471276Demanes gets excellent outcomes in intermediate risk patients with HDR brachy monotherapy without adding the toxicity of ADT. This was true for unfavorable intermediate risk patients as well:
High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer